Cancer cell therapy advancements: How Carvykti is changing the game

In the field of cancer treatment, biological therapies like CAR-T therapy, gene therapy, and monoclonal antibodies are emerging as promising options that can surpass the limited effectiveness of chemotherapy. However, researchers are aware of the potential side effects of biological therapy and are actively working to improve its effectiveness while reducing its negative impact. According to BioIntel360, the global cell and gene therapy market is expected to expand significantly, recording a projected Compound Annual Growth Rate (CAGR) of 26.2% between 2023-2027. By 2027, the market size is anticipated to reach US$53,950.5 million, up from US$21,293.4 million in 2023. Over the past five years, the sector has grown at a CAGR of 28.0%, and in 2022 it was valued at US$16,734.3 million.

One of the significant breakthroughs in cancer biological therapies is gene therapy. A diverse range of gene therapy approaches is currently being explored, including anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, immune modulation based on gene therapy, oncolytic virotherapy, gene defect correction/compensation, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNA interference strategies. The use of oncolytic viruses is a promising approach that can selectively target cancer cells while sparing healthy ones by activating natural killer cells. Furthermore, oncolytic virotherapy has garnered significant research funding to advance its development.

In July 2022, the researchers at the Center for Nuclear Receptors and Cell Signaling at the University of Houston received a $1.8 million grant from the National Institutes of Health to work on oncolytic virotherapy.

Another area in cancer biological therapies is CAR T cell therapy, which equips T cells to detect and destroy cancer cells that hide from the immune system. The rise in cancer cases is expected to drive the demand for CAR T cell therapy. Ongoing research and development efforts are also contributing to the growth of this therapy.

For example, Novartis launched the next-generation CAR-T platform T-Charge in December 2021, which is intended to set the groundwork for several new investigational CAR T cell therapeutics in the Novartis pipeline.
In a late-stage clinical trial, Johnson & Johnson and Legend Biotech's cancer cell treatment, Carvykti, beat conventional medications in treating the blood malignancy multiple myeloma. In comparison to standard of care, Carvykti reduced the probability of disease progression or death by 74%, according to data from a research abstract that was hacked and temporarily released online. The primary objective of median progression-free survival was not yet met in the Carvykti group, compared to 12 months for those receiving standard of care, in the research of patients who had undergone one to three prior therapies.
Carvykti is a CAR-T therapy that is created from immune cells taken from each patient and genetically modified to target proteins identified on cancer cells' surfaces. Currently, patients with multiple myeloma who have taken at least four prior medications can use it in the US, but J&J and Legend want to extend its clearance to include earlier lines of therapy.
The 74% risk reduction was deemed "stellar" and "game-changing efficacy" by analysts, who cited it as "highly encouraging for adoption" in the context of second-line treatment. Carvykti competes with Bristol Myers Squibb's Abecma, a different CAR-T treatment, in the US. The two treatments both target the BCMA protein, and while Abecma lowered the risk of disease progression and mortality by 51% in a trial that was basically similar to this one, there are certain design differences between the two studies that make it more challenging to establish an apples-to-apples comparison.
The production of their various cures, which are complex to create and necessitate cautious transportation, has proven challenging for both Bristol Myers and J&J. Carvykti did, however, earn $72 million between January and March, according to J&J's recently released first quarter sales numbers, which were better than anticipated. According to J&J CFO Joe Wolk, manufacturing is ramping up to supply markets, and the business has a manufacturing agreement in place with Novartis to assist with the production of Carvykti.

BioIntel360 suggests that the clinical trial results for Carvykti that were disclosed indicate that the medication is quite effective in treating multiple myeloma. Personalised medicines like Carvykti continue to face manufacturing challenges, but J&J and Legend's partnership with Novartis may help to resolve these problems. The future of cancer cell therapy looks promising, with several advancements being made in this field.

Researchers are now exploring the use of CAR T cell therapy in treating other types of cancer, such as solid tumors. There are ongoing clinical trials to test the safety and effectiveness of this therapy in various cancers, including breast cancer, lung cancer, and prostate cancer. The results so far have been encouraging, and BioIntel360 expects that CAR T cell therapy is likely to become a standard treatment option for more cancer types in the future.